In this edition:
HARMONi-2: ivonescimab vs. pembrolizumab in PD-L1-positive advanced NSCLC
NeoCOAST: neoadjuvant therapies for resectable, early-stage NSCLC
CheckMate 77T vs. 816: perioperative vs. neoadjuvant nivolumab for resectable NSCLC
A predictive biomarker for clinical outcomes in TROPION-Lung01
PanCan vs. LungRADSv1.1 for LDCT screening
SOHO-01: BAY 2927088 in HER2-altered NSCLC
Beamion LUNG-1: zongertinib in HER2-altered NSCLC
FURTHER: firmonertinib in NSCLC with EGFR PACC mutations
FLOWERS: osimertinib ± savolitinib in de novo MET-aberrant, EGFR-mutated NSCLC
POLESTAR: aumolertinib maintenance after chemoradiotherapy in stage III NSCLC
Please login below to download this issue (PDF)